Tickers
Lyell Immunopharma (LYEL) was upgraded to “Buy” as its pivotal ronde-cel CAR-T programs advance in relapsed/refractory large B-cell lymphoma. The company raised $80 million in a private placement, extending its cash runway into 2028 to fund ongoing pivotal and phase 3 trials. Upcoming catalysts include ASH 2026 data for ronde-cel in second/third-line r/r LBCL and phase 1/2 data for LYL273 in metastatic colorectal cancer.
Lyell Immunopharma (LYEL) has been upgraded to “Buy” as its pivotal ronde-cel CAR-T programs advance in relapsed/refractory large B-cell lymphoma (r/r LBCL), according to a Seeking Alpha article published November 5, 2026.
Financing Extends Runway
The company secured $80 million in a private placement. According to the source, the funding extends Lyell’s cash runway into 2028 and supports its ongoing pivotal and phase 3 trials.
Upcoming Catalysts
The article identifies two key catalysts for the company:
- ASH 2026: Data updates for ronde-cel in second- and third-line r/r LBCL.
- Phase 1/2 data: Results for LYL273 in metastatic colorectal cancer.
Context
The upgrade is tied to the advancement of the ronde-cel CAR-T programs in r/r LBCL, alongside the additional capital from the private placement.